Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.
Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F, Mizuno R, Okamoto T, Okuno H, Ito T, Kajita M, Oya M, Tomita Y, Shinohara N, Eto M, Uemura H. Kato T, et al. Among authors: oya m. Int J Clin Oncol. 2024 Nov 16. doi: 10.1007/s10147-024-02618-9. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39549218
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.
Armstrong AJ, Clarke N, Oya M, Procopio G, de Menezes J, Guedes JD, Ghatalia P, Nolè F, Din O, Spiegelhalder P, Mincik I, van Alphen R, Lumen N, Hosius C, Zhou D, Barker L, Dujka M, Saad F. Armstrong AJ, et al. Among authors: oya m. Eur Urol Oncol. 2023 Oct 27:S2588-9311(23)00218-3. doi: 10.1016/j.euo.2023.10.004. Online ahead of print. Eur Urol Oncol. 2023. PMID: 39492050 Free article.
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.
Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Clarke NW, et al. Among authors: oya m. Eur Urol Oncol. 2024 Oct 8:S2588-9311(24)00222-0. doi: 10.1016/j.euo.2024.09.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39384451 Free article.
Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial.
Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, Komai Y, Fujiwara R, Sato Y, Sugimoto M, Tsuzuki T, Fujimoto K, Inoue K, Oya M. Taoka R, et al. Among authors: oya m. Int J Clin Oncol. 2024 Oct 7. doi: 10.1007/s10147-024-02638-5. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39375287
1,231 results